KAL
12.9.2019 15:07:09 CEST | Business Wire | Press release
Market-leading ATM software company KAL is launching Kalignite Hypervisor, a game-changing new product for the retail banking industry that solves the long-standing, billion-dollar problem of enforced ATM hardware upgrades.
Kalignite Hypervisor uses Red Hat Virtualization to decouple the ATM PC core from the ATM operating system. This means software drivers that are unsupported under new Windows operating system versions can now be supported by the hypervisor’s software drivers instead.
The Kalignite Hypervisor breaks the straitjacket of unsupported hardware when migrating ATMs to Windows 10. It gives banks the freedom to upgrade software and hardware at a time that suits them. Better still, it is not only a solution for today. OS upgrades are set to happen more frequently in the future in the form of Windows LTSC and SAC packages ‒ which Microsoft plan to release regularly – resulting in hardware obsolescence occurring at a quicker pace. Not only is Kalignite Hypervisor important when migrating to Windows 10, it will become essential when managing these new software upgrades.
KAL CEO Aravinda Korala said: “Kalignite Hypervisor solves the upgrade conundrum. It eliminates the need for enforced hardware upgrades caused by Windows upgrades. Banks can stay completely up to date and run the latest versions of all software on their ATM network – bringing them freedom at last from the enforced hardware upgrade cycle, and allowing them to focus on enhancements that matter to their customers.”
Red Hat Cloud Platforms vice president of products Joe Fernandes said “Using open, software-defined virtualization platforms like Red Hat Virtualization, banks are able to manage the upgrade cycles for their hardware and software separately. This gives them greater flexibility and control over the process and enables them to be more strategic in how they upgrade their ATM PC cores.”
Kalignite Hypervisor is available to banks directly from KAL. Alternatively, banks can ask their current software vendor about an OEM version of the KAL product. This is specially designed with open APIs for ATM hardware and software vendors that wish to integrate KAL’s hypervisor technology with their own software stacks.
About KAL
KAL is a world-leading ATM software company and the preferred supplier to world mega-banks such as Erste, ING, Citibank, UniCredit, HSBC and China Construction Bank. KAL’s software gives banks full control of their ATM network, reducing costs and improving speed to market.
For more information, visit www.kal.com
Red Hat is a trademark or registered trademark of Red Hat, Inc. or its subsidiaries in the U.S. and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005411/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom